Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Knight Therapeutics ( (TSE:GUD) ) is now available.
Knight Therapeutics reported record 2025 revenues of $450.1 million and its highest-ever adjusted EBITDA and operating cash flow since inception, driven largely by contributions from the Paladin and Sumitomo acquisitions and strong growth in key promoted products. Despite these gains, gross margin declined, and the company posted a net loss due to inflation impacts, inventory fair-value adjustments, and pressure in mature and branded generic portfolios.
The company strengthened its balance sheet and capital structure with a new US$100 million syndicated revolving credit facility, a working capital line, and the settlement of the Synergy loan, while also repurchasing over 1.1 million shares under its NCIB. Looking ahead, Knight issued 2026 guidance calling for revenues between $490 million and $510 million and an adjusted EBITDA margin of about 15%, signaling confidence in continued portfolio growth and integration of recent acquisitions.
The most recent analyst rating on (TSE:GUD) stock is a Buy with a C$7.45 price target. To see the full list of analyst forecasts on Knight Therapeutics stock, see the TSE:GUD Stock Forecast page.
Spark’s Take on GUD Stock
According to Spark, TipRanks’ AI Analyst, GUD is a Neutral.
Knight Therapeutics’ overall score is driven by strong earnings call performance, showcasing significant revenue and EBITDA growth. However, challenges in profitability, cash flow, and valuation metrics weigh down the score. The technical analysis indicates a neutral market sentiment.
To see Spark’s full report on GUD stock, click here.
More about Knight Therapeutics
Knight Therapeutics Inc. is a Montreal-based specialty pharmaceutical company focused on the pan-American markets outside the U.S. It builds a portfolio of key promoted products and growth brands, including assets acquired through the Paladin and Sumitomo transactions, while managing a base of mature and branded generic products across the region.
Average Trading Volume: 91,087
Technical Sentiment Signal: Buy
Current Market Cap: C$604.9M
For a thorough assessment of GUD stock, go to TipRanks’ Stock Analysis page.